Valo Health Inc. has disclosed tricyclic phthalazinone compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Monte Rosa Therapeutics Inc. has described molecular glue degraders comprising cereblon ligands and a casein kinase 1 Isoform α (CK1α) targeting moiety acting as CK1α degradation inducers reported to be useful for the treatment of cancer.
Researchers at Jiangsu Hengrui Medicine Co. Ltd., Shanghai Fourth People’s Hospital Affiliated Tongji University and Shanghai Senhui Pharmaceutical Co. Ltd. have divulged cyclopentyl adenosine derivatives reported to be useful for the treatment of chronic pain.
Researchers from Florey Neuroscience Institutes, Monash University and Olivia Newton-John Cancer Research Institute have identified fluorine-radiolabeled compounds acting as tyrosine-protein kinase Mer (MERTK) inhibitors and also as positron emission tomography (PET) imaging agents reported to be useful for the diagnosis and treatment of multiple sclerosis (MS).
Hinova Pharmaceuticals Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to an estrogen receptor (ER)-targeting moiety through a linker.
Boehringer Ingelheim Pharma GmbH & Co. KG has identified 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
RSS